CSIMarket
 


Gentium S.p.a.  (GENT)
Other Ticker:  
 

Cumulative Gentium S.p.a.'s Working Capital Ratio for Trailing Twelve Months Period

GENT's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

GENT Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2013)
IV. Quarter
0
III. Quarter
(Jun 30 2013)
II. Quarter
0
I. Quarter
(Dec 31 2012)
FY
Y / Y Current Liabilities Growth 35.05 % 6.41 % - - -
Y / Y Current Assets Growth 28.53 % 43.21 % - - -
Working Capital Ratio for Trailing Twelve Months Period 3.96 4 3.74 3.66 3.48
Total Ranking # # 323 # # #
Seq. Current Liabilities Growth 0 % 0 % 0 % 35.05 % -21.21 %
Seq. Current Assets Growth 0 % 0 % 0 % 28.53 % 11.42 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2013
On the trailing twelve months basis Due to unchange in Current Liabilities in the IV. Quarter to $7 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 3.96 below Gentium S.p.a. average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Gentium S.p.a.. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about GENT
Working Capital Ratio GENT in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 18
Sector # 89
S&P 500 # 412


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
3.09 3.09 3.09
0  




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2013, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Pluri Inc   10.07 
Repligen Corp  7.78 
Aevi Genomic Medicine, Inc.  7.77 
Adma Biologics Inc   7.56 
Compugen Ltd  7.53 
Novavax inc  7.43 
Bluebird Bio Inc   7.14 
Cannabis Global Inc.  7.00 
Vaxart Inc   6.91 
Sorrento Therapeutics Inc   6.60 
Trius Therapeutics Inc  6.18 
Aceragen Inc   5.73 
Acceleron Pharma inc  5.57 
Fate Therapeutics Inc   5.25 
China Biologic Products Holdings Inc   5.16 
Viropharma Inc  4.80 
Cel sci Corporation  4.54 
Amgen Inc   4.53 
Seagen Inc   4.49 
Receptos, Inc.  4.36 
Organovo Holdings Inc   4.31 
Halozyme Therapeutics Inc   4.24 
Telik Inc  4.14 
Exelixis Inc   4.06 
Gentium S.p.a.  4.00 
Brainstorm Cell Therapeutics inc   3.92 
Windtree Therapeutics Inc  3.92 
Acorda Therapeutics Inc   3.89 
Savient Pharmaceuticals Inc  3.81 
Nanostring Technologies Inc   3.76 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com